Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer
NCT00143403
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Histologically proven adenocarcinoma of the colon or rectum with complete resection of primary tumour.
- Complete surgical resection (R0) of the liver metastasis(es) within a minimum of 3 weeks, and a maximum of 8 weeks prior to the first study treatment infusion.
- Exclusively hepatic metastasis (es) : absence of bone, lung and brain metastases.
- Prior hepatic radiation or resection.
- Prior radiofrequency ablation or cryoablation Incomplete surgical resection of liver
metastasis (es).
- Prior chemotherapy for metastatic disease.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Gent,
- Roeselare,
- Copenhagen,
- Herlev,
- Odense,
- Amiens cedex 1,
- Avignon,
- Boulogne Billancourt cedex,
- Clermont-Ferand Cedex 1,
- Colmar,
- Grenoble Cedex 09,
- Marseille Cedex 9,
- Marseille,
- Marseille,
- Montpellier Cedex 5,
- Montpellier,
- Nice,
- Nimes,
- Rennes,
- Strasbourg,
- Toulouse cedex,
- Cottbus,
- Dessau,
- Erlangen,
- Hamburg,
- Leipzig,
- Magdeburg,
- Magdeburg,
- Mainz,
- Oldenburg,
- Regensburg,
- Tuebingen,
- Hong Kong,
- Haifa,
- Petach-Tikva,
- Rehovot,
- Tel-Aviv,
- Tel-Hashomer,
- Carpi, Modena
- Brescia,
- Latisana, UD,
- Padova,
- Parma,
- Piacenza,
- Reggio Emilia,
- Rozzano (Mi),
- Daegu,
- Goyang,
- Seoul,
- Seoul,
- Seoul,
- Porto,
- Panorama, Cape Town
- L'Hospitalet de Llobregat, Barcelona
- Santander, Cantabria
- Barcelona,
- Madrid,
- Sevilla,
- Goteborg,
- Bern,
- Taoyuan,
- Donetsk,
- Kiev,
- London,
- Southampton,
- Surrey,
- New York, New York
- Philadelphia, Pennsylvania
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer | |||
Official Title ICMJE | Multi-Centre Phase III Open Label Randomized Trial Comparing CPT-11 In Combination With A 5-FU/FA Infusional Regimen To The Same 5-FU/FA Infusional Regimen Alone, As Adjuvant Treatment After Resection Of Liver Metastases For Colorectal Cancer. | |||
Brief Summary | To see if Disease Free Survival (DFS) is improved when complete surgical resection of liver metastases (R0) is followed by chemotherapy with CPT-11 and 5-FU/FA as FOLFIRI regimen, compared to 5-FU/FA alone. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE |
| |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 321 | |||
Original Enrollment ICMJE | 420 | |||
Actual Study Completion Date ICMJE | September 2009 | |||
Actual Primary Completion Date | February 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 75 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Belgium, Denmark, France, Germany, Hong Kong, Israel, Italy, Korea, Republic of, Portugal, South Africa, Spain, Sweden, Switzerland, Taiwan, Ukraine, United Kingdom | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00143403 | |||
Other Study ID Numbers ICMJE | CPT-GMA-301 A5961076 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer Inc | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | September 2010 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |